- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01480700
Consumption of Eggs Rich in Lutein and Omega-3 Fatty Acids on the Macular Pigment (ALGOVUE)
August 2, 2013 updated by: Jean-Michel Lecerf, Institut Pasteur de Lille
Effect of Consumption of Eggs Rich in Xanthophyll Carotenoids and Omega-3 Fatty Acids on the Macular Pigment in Healthy People
This study is to determine the impact of the consumption of eggs rich in lutein/zeaxanthin from lucerne protein concentrate and DHA from microalgae on the plasma levels of these compounds but also on the macular pigment optical density, whose elevation may be beneficial in the prevention of Age-related Macular Degeneration (AMD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
99
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lille, France, 59000
- Institut Pasteur de Lille
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy subjects (male or female),
- 18 to 55 years
- Having signed the consent form,
- Susceptible to accept the stresses generated by the study,
- Insured.
Exclusion Criteria:
- Corrected Visual Acuity <8/10th,
- History of cardiovascular disease, specifically coronary heart disease,
Characterized dyslipidemia
* Total cholesterol ³ 2.50 g / L, and / or triglycerides ³ 2.00 g / L
- Lipid-lowering treatment,
- Current smoking or person who stopped smoking less than 6 months
- Cataract or cataract surgery,
- Diabetes
- Body Mass Index (BMI)> 30 kg/m2,
- Taking food supplements in the 3 months preceding the start of the study (carotenoids, omega-3 fatty acids, phytosterols),
- Regular consumption in the three months preceding the start of the study products with added phytosterols.
- Regular consumption of high fatty fish or shellfish rich in omega-3 (4x a week or more): salmon, sardines, mackerel, herring, trout, tuna, red mullet, sea bass, bream, farmed turbot, mussels, squid / squid, anchovies.
- Allergy to eggs
- Dieting
- Difference significant weight over the last 3 months (> 3 kg)
- Inability to understand or adhere to the protocol
- Persons deprived of liberty
- People in a position to judicial protection
- Pregnant Women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rich-eggs
subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
|
subjects consume 2 eggs per day during 4 months
|
Active Comparator: standard eggs
subjects consume 2 standard eggs per day
|
subjects consume 2 eggs per day during 4 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change from baseline in optical density of macular pigment after 4 months of eggs consumption
Time Frame: before the eggs consumption and four months afterwards
|
optical density of macular pigment was measured with a Heidelberg Retinal Angiograph (HRA)specially modify for the measure of the pigment.
|
before the eggs consumption and four months afterwards
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change from baseline in lutein and zeaxanthin in plasma and lipoproteins after 4 months of egg consumption
Time Frame: before the eggs consumption and four months afterwards
|
lutein and zeaxanthin were measured by HPLC
|
before the eggs consumption and four months afterwards
|
change from baseline in fatty acids in plasma and lipoproteins after 4 months of egg consumption
Time Frame: before the eggs consumption and four months afterwards
|
Fatty acids were measured by Gas Chromatography.
|
before the eggs consumption and four months afterwards
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jean-Michel LECERF, MD, Institut Pasteur de Lille
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Actual)
February 1, 2013
Study Completion (Actual)
February 1, 2013
Study Registration Dates
First Submitted
September 13, 2011
First Submitted That Met QC Criteria
November 28, 2011
First Posted (Estimate)
November 29, 2011
Study Record Updates
Last Update Posted (Estimate)
August 5, 2013
Last Update Submitted That Met QC Criteria
August 2, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-A00364-37
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
Clinical Trials on Nutritional study
-
Abbott NutritionCompleted
-
University of MichiganRecruiting
-
Abbott NutritionWithdrawn
-
Abbott NutritionCompleted
-
University of SouthamptonNational University Hospital, Singapore; Singapore Institute for Clinical Sciences and other collaboratorsCompletedHyperglycemiaSingapore, United Kingdom, New Zealand
-
University Health Network, TorontoRecruiting
-
Stanford UniversityTerminated
-
Abbott NutritionCompleted
-
Abbott NutritionCompleted
-
Johannes Gutenberg University MainzUniversity of JenaCompletedNon-alcoholic Fatty Liver Disease | Fatty Liver, NonalcoholicGermany